LC
URGN icon

Lindbrook Capital’s UroGen Pharma URGN Stock Holding History

Lindbrook Capital’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-87
Closed -$1.46K – 2913
2024
Q2 		$1.46K Sell
87
-73
-46% -$1.04K ﹤0.01% 2428
2024
Q1 		$2.4K Buy
160
+98
+158% +$1.6K ﹤0.01% 2173
2023
Q4 		$930 Buy
+62
New +$805 ﹤0.01% 2479
2021
Q4 		– Sell
-513
Closed -$9K – 2207
2021
Q3 		$9K Buy
513
+341
+198% +$5.41K ﹤0.01% 1055
2021
Q2 		$3K Sell
172
-106
-38% -$1.92K ﹤0.01% 1517
2021
Q1 		$5K Sell
278
-78
-22% -$1.66K ﹤0.01% 1279
2020
Q4 		$6K Sell
356
-13
-4% -$272 ﹤0.01% 1140
2020
Q3 		$7K Sell
369
-121
-25% -$2.74K ﹤0.01% 982
2020
Q2 		$13K Buy
490
+291
+146% +$7.11K ﹤0.01% 749
2020
Q1 		$4K Sell
199
-71
-26% -$1.92K ﹤0.01% 1122
2019
Q4 		$9K Buy
+270
New +$7.37K ﹤0.01% 958

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Lindbrook Capital's URGN Position: Q3 2024 in Review

Lindbrook Capital sold out of UroGen Pharma (URGN) in Q3 2024, closing a stake of 87 shares — an estimated $1.46K sold.

Lindbrook Capital first reported a position in URGN in Q4 2019 and held it in 11 quarters. The position peaked at $13K in Q2 2020. 128 funds tracked by Wall St. Rank hold URGN as of Q3 2024.

  • Lindbrook Capital reported no remaining UroGen Pharma position as of Q3 2024 after selling out during the quarter.
  • Lindbrook Capital sold 87 UroGen Pharma shares in Q3 2024, an estimated $1.46K.
  • Lindbrook Capital first reported a position in UroGen Pharma in Q4 2019 and held it in 11 quarters.
  • Lindbrook Capital's UroGen Pharma position peaked at $13K in Q2 2020.
  • 128 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2024.

Based on Lindbrook Capital's 13F filing for Q3 2024, filed 1 Nov 2024.